Skip to content
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Clinical Genetics · Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorder

What Causes hEDS and HSD If There Is No Genetic Test?

At a Glance

hEDS and HSD do not currently have a validated genetic or blood test. Doctors diagnose them using joint flexibility, symptoms, medical and family history, and by ruling out other disorders; research is still investigating inherited, connective-tissue, and nervous-system factors.

People often wonder how a condition like hypermobile Ehlers-Danlos syndrome (hEDS) or hypermobility spectrum disorder (HSD) can be diagnosed and treated if there is no genetic test to prove it exists. The short answer is that hEDS and HSD are real, measurable clinical conditions, but their underlying cause has not yet been linked to a single mutated gene that a standard test can spot [1][2].

While other rarer types of EDS (like Classical or Vascular EDS) have identifiable single-gene mutations affecting specific types of collagen [3], hEDS and HSD likely result from a complex interaction of inherited susceptibility, connective tissue differences, and nervous system responses [1][4]. A lack of a single biomarker means that science is still working to map out the exact molecular steps, but scientific uncertainty about the exact cause is not a dismissal of your symptoms [5].

hEDS vs. HSD: Clinical Diagnoses

Because there is no blood test, diagnosis relies on a clinician’s evaluation:

  • hEDS is diagnosed using strict, internationally defined clinical criteria that look for generalized joint hypermobility alongside specific systemic features and family history, while ruling out other conditions [6].
  • HSD is diagnosed when a person has symptomatic joint hypermobility but does not meet the strict criteria for hEDS or another specific connective tissue disorder [4].

HSD is not simply “mild hEDS”—symptoms can be severe and disabling in either condition [7].

What is Established vs. What is Still Being Studied

What is Established What is Still Being Studied
Clinical Diagnosis: hEDS and HSD are diagnosed via physical exam, history, and symptom criteria [6]. Exact Genetic Cause: Researchers are exploring polygenic models and candidate genes [1][8].
No Validated Biomarker: There is currently no blood or genetic test to confirm hEDS or HSD [5]. Tissue Changes: Cell and matrix abnormalities seen in lab studies are not yet routine clinical tests [9].
Genetic Testing for Other Conditions: Testing is used to rule out other rarer disorders [2]. Symptom Mechanisms: The exact roles of nerve signaling, proprioception, and dysautonomia [10].

Connective Tissue and Extracellular Matrix Studies

Even without a genetic test, researchers are finding physical differences in the tissues of people with hEDS and HSD in research settings. Studies looking at fibroblasts—the cells responsible for building the body’s connective tissues—show that they behave differently in some patients [9].

In a healthy body, the extracellular matrix (ECM) acts as a highly organized biological scaffolding that holds cells and tissues together. In laboratory studies of hEDS and HSD samples, this scaffolding sometimes shows signs of disorganization, with altered patterns of collagen, elastin, and fibronectin [9][11]. The fibroblasts themselves may show increased matrix-degrading activity, meaning the body remodels this scaffolding abnormally [12].

It is important to note that these are preliminary findings from selected research samples, not universal diagnostic biomarkers [9]. Additionally, while people with hEDS may experience mild skin changes or bruising, severe skin fragility, characteristic scarring, or unusual vascular or organ ruptures are not standard for hEDS and warrant evaluation for other rarer connective tissue disorders [2].

A Complex Genetic Hypothesis

Because hEDS frequently runs in families, researchers know there is an inherited component [4]. However, the exact causal architecture remains unresolved [8]. One leading hypothesis is that hEDS and HSD might be “polygenic,” meaning multiple gene variants interact with developmental and environmental factors to produce the symptoms [1][13].

Scientists are actively researching several promising genetic clues. For example, recent studies (published between 2021 and 2024) have identified associations with a gene family called KLK15 in some families, and other large-scale studies have found genetic signals near a gene called ACKR3 [14][15]. These are preliminary candidate findings, not established causes or accepted diagnostic markers [8].

Currently, when doctors order genetic testing for someone with hypermobility, it is usually to identify or rule out other rare connective tissue disorders [2][16]. A negative genetic panel does not rule out hEDS or HSD, and panels can sometimes return “variants of uncertain significance,” which do not definitively establish or exclude a diagnosis [16].

Pain Processing and the Nervous System

The chronic pain associated with hEDS and HSD involves more than just mechanical joint wear-and-tear. Symptoms can be severe even when an X-ray shows little structural change, because imaging does not measure pain or soft-tissue instability [10].

  • Central Sensitization: Some patients develop central sensitization, a condition where the central nervous system becomes hyper-reactive, amplifying pain signals [17]. This is a possible contributor to widespread pain, rather than a universal rule [17].
  • Small-Fiber Neuropathy: Some studies in specialty clinics have found reduced small nerve-fiber density or abnormal nerve testing in a portion of patients with hEDS [18][10]. This can contribute to burning or electrical-type pain, though such pain has other possible causes, and small-fiber testing is individualized rather than a routine confirmation test for hEDS/HSD [18].

Autonomic and Movement Contributors

Issues often extend to the autonomic nervous system (which controls background functions like heart rate and blood pressure) [19]. Conditions like postural orthostatic tachycardia syndrome (POTS) and orthostatic intolerance are reported more frequently in some hypermobility cohorts [19][20]. Researchers hypothesize this could be linked to altered nerve function, connective tissue laxity, or abnormal blood flow regulation [21]. However, POTS is not part of the hEDS diagnostic criteria, and symptoms like dizziness or rapid heart rate always require formal clinical assessment to rule out other causes (like anemia, medication effects, or endocrine issues) [6][19].

Finally, impaired proprioception—the brain’s ability to sense where the body’s joints are in space—is a proposed mechanism for fatigue [22][10]. When joints are unstable, studies suggest that altered muscle activation or tendon stiffness may occur as the body tries to compensate [23]. This overcompensation is a possible contributor to movement-related pain and fatigue [23].

Glossary of Key Terms

  • Dysautonomia: Dysfunction of the autonomic nervous system, which controls automatic body functions like heart rate and blood pressure.
  • Extracellular Matrix (ECM): The biological “scaffolding” of proteins (like collagen and elastin) that provides structure to tissues.
  • Fibroblasts: Cells that synthesize the extracellular matrix and collagen.
  • Polygenic: A condition caused by the combined effect of multiple genes, rather than a single gene.
  • Proprioception: The body’s ability to sense its position and movement in space without relying on vision.

Common questions in this guide

Can I have hEDS or HSD if genetic testing is negative?
Yes. hEDS and HSD are diagnosed clinically using medical history, physical examination, joint-hypermobility findings, and symptom criteria rather than a confirmatory genetic test. A negative genetic panel does not rule out either condition.
What is thought to cause hEDS and HSD?
The exact cause is not known. Researchers suspect that inherited susceptibility involving multiple genes may interact with connective-tissue differences and changes in pain processing, automatic body functions, or movement control. These explanations are still being studied and are not single diagnostic tests.
How are hEDS and HSD different?
hEDS is diagnosed when a person meets strict criteria that include generalized joint hypermobility plus certain additional features and the exclusion of other conditions. HSD is diagnosed when symptomatic joint hypermobility is present but the person does not meet hEDS criteria or criteria for another specific connective-tissue disorder. HSD is not simply mild hEDS, and symptoms can be severe in either condition.
Why would a doctor order genetic testing for someone with hypermobility?
Genetic testing is usually used to look for or rule out other rare connective-tissue disorders that have known gene changes, not to confirm hEDS or HSD. Results may be negative or may show a variant of uncertain significance, which does not establish or exclude either diagnosis. Your clinician can explain what a test result would change in your care.
Can dizziness, a fast heart rate, or nerve pain be related to hEDS or HSD?
Some people with hypermobility report dizziness when standing, rapid heart rate, orthostatic intolerance, or burning and electrical-type pain. These symptoms can have several causes, and postural orthostatic tachycardia syndrome is not part of the hEDS diagnostic criteria. They should be evaluated separately so conditions such as anemia, medication effects, or endocrine problems are not missed.
Can fibroblast or connective-tissue testing diagnose hEDS?
Research studies have found differences in fibroblasts and the connective-tissue scaffold in some people with hEDS or HSD. These findings are preliminary and are not universal, validated tests used to diagnose either condition in routine care. Diagnosis still relies on clinical evaluation.

Get notified when new evidence is published on hypermobility syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (23)
  1. 1

    Deconstructing and reconstructing joint hypermobility on an evo-devo perspective.

    Castori M

    Rheumatology (Oxford, England) 2021; (60(6)):2537-2544 doi:10.1093/rheumatology/keab196.

    PMID: 33668066
  2. 2

    Hypermobile Ehlers-Danlos Syndrome: Diagnostic Challenges and the Role of Genetic Testing.

    Forghani I, See J, McGonigle WC

    Genes 2025; (16(5)) doi:10.3390/genes16050530.

    PMID: 40428350
  3. 3

    The Role of Cell Adhesion and Cytoskeleton Dynamics in the Pathogenesis of the Ehlers-Danlos Syndromes and Hypermobility Spectrum Disorders.

    Malek S, Köster DV

    Frontiers in cell and developmental biology 2021; (9()):649082 doi:10.3389/fcell.2021.649082.

    PMID: 33968931
  4. 4

    Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders.

    Yew KS, Kamps-Schmitt KA, Borge R

    American family physician 2021; (103(8)):481-492.

    PMID: 33856167
  5. 5

    Updates in Clinical and Genetics Aspects of Hypermobile Ehlers Danlos Syndrome

    Forghani I

    Balkan medical journal 2019; (36(1)):12-16 doi:10.4274/balkanmedj.2018.1113.

    PMID: 30063214
  6. 6

    Looking back and beyond the 2017 diagnostic criteria for hypermobile Ehlers-Danlos syndrome: A retrospective cross-sectional study from an Italian reference center.

    Ritelli M, Chiarelli N, Cinquina V, et al.

    American journal of medical genetics. Part A 2024; (194(2)):174-194 doi:10.1002/ajmg.a.63426.

    PMID: 37774134
  7. 7

    Subtle differences in autonomic symptoms in people diagnosed with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders.

    Martinez KL, Mauss C, Andrews J, et al.

    American journal of medical genetics. Part A 2021; (185(7)):2012-2025 doi:10.1002/ajmg.a.62197.

    PMID: 33826221
  8. 8

    Hypermobile Ehlers-Danlos syndrome: A review and a critical appraisal of published genetic research to date.

    Scicluna K, Formosa MM, Farrugia R, Borg I

    Clinical genetics 2022; (101(1)):20-31 doi:10.1111/cge.14026.

    PMID: 34219226
  9. 9

    RNA-Seq of Dermal Fibroblasts from Patients with Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders Supports Their Categorization as a Single Entity with Involvement of Extracellular Matrix Degrading and Proinflammatory Pathomechanisms.

    Ritelli M, Chiarelli N, Cinquina V, et al.

    Cells 2022; (11(24)) doi:10.3390/cells11244040.

    PMID: 36552803
  10. 10

    Pain in hypermobile Ehlers-Danlos syndrome: New insights using new criteria.

    Bénistan K, Martinez V

    American journal of medical genetics. Part A 2019; (179(7)):1226-1234 doi:10.1002/ajmg.a.61175.

    PMID: 31075184
  11. 11

    Transcriptome-Wide Expression Profiling in Skin Fibroblasts of Patients with Joint Hypermobility Syndrome/Ehlers-Danlos Syndrome Hypermobility Type.

    Chiarelli N, Carini G, Zoppi N, et al.

    PloS one 2016; (11(8)):e0161347 doi:10.1371/journal.pone.0161347.

    PMID: 27518164
  12. 12

    Dermal fibroblast-to-myofibroblast transition sustained by αvß3 integrin-ILK-Snail1/Slug signaling is a common feature for hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders.

    Zoppi N, Chiarelli N, Binetti S, et al.

    Biochimica et biophysica acta. Molecular basis of disease 2018; (1864(4 Pt A)):1010-1023 doi:10.1016/j.bbadis.2018.01.005.

    PMID: 29309923
  13. 13

    Matrix Metalloproteinases Inhibition by Doxycycline Rescues Extracellular Matrix Organization and Partly Reverts Myofibroblast Differentiation in Hypermobile Ehlers-Danlos Syndrome Dermal Fibroblasts: A Potential Therapeutic Target?

    Chiarelli N, Zoppi N, Venturini M, et al.

    Cells 2021; (10(11)) doi:10.3390/cells10113236.

    PMID: 34831458
  14. 14

    KLK15 alters connective tissues in hypermobile Ehlers-Danlos syndrome.

    Gensemer C, Petrucci T, Beck T, et al.

    iScience 2025; (28(9)):113343 doi:10.1016/j.isci.2025.113343.

    PMID: 40949095
  15. 15

    Complex Genetics and Regulatory Drivers of Hypermobile Ehlers-Danlos Syndrome: Insights from Genome-Wide Association Study Meta-analysis.

    Petrucci-Nelson T, Guilhaumou S, Berrandou TE, et al.

    medRxiv : the preprint server for health sciences 2025; doi:10.1101/2025.09.19.25336146.

    PMID: 41001447
  16. 16

    Genetic complexity of diagnostically unresolved Ehlers-Danlos syndrome.

    Vandersteen AM, Weerakkody RA, Parry DA, et al.

    Journal of medical genetics 2024; (61(3)):232-238 doi:10.1136/jmg-2023-109329.

    PMID: 37813462
  17. 17

    Linking central sensitization to multisystemic manifestations in hypermobile Ehlers-Danlos syndrome.

    Montemayor Zarazúa AP, Elizondo Solis CV, Ayala García C, et al.

    Frontiers in pain research (Lausanne, Switzerland) 2026; (7()):1799439 doi:10.3389/fpain.2026.1799439.

    PMID: 42454246
  18. 18

    Skin biopsy reveals generalized small fibre neuropathy in hypermobile Ehlers-Danlos syndromes.

    Igharo D, Thiel JC, Rolke R, et al.

    European journal of neurology 2023; (30(3)):719-728 doi:10.1111/ene.15649.

    PMID: 36437696
  19. 19

    A new insight on postural tachycardia syndrome in 102 adults with hypermobile Ehlers-Danlos Syndrome/hypermobility spectrum disorder.

    Celletti C, Borsellino B, Castori M, et al.

    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace 2020; (90(2)) doi:10.4081/monaldi.2020.1286.

    PMID: 32434316
  20. 20

    Hypermobile Ehlers-Danlos Syndrome: Cerebrovascular, Autonomic and Neuropathic Features.

    Novak P, Systrom DM, Marciano SP, et al.

    American journal of medicine open 2025; (14()):100111 doi:10.1016/j.ajmo.2025.100111.

    PMID: 40843452
  21. 21

    Dysautonomia in hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders is associated with exercise intolerance and cardiac atrophy.

    Ruiz Maya T, Fettig V, Mehta L, et al.

    American journal of medical genetics. Part A 2021; (185(12)):3754-3761 doi:10.1002/ajmg.a.62446.

    PMID: 34331416
  22. 22

    Clinical characteristics of patients with hypermobile type Ehlers-Danlos syndrome (hEDS) and generalized hypermobility spectrum disorders (G-HSD): an online survey.

    Teran-Wodzinski P, Kumar A

    Rheumatology international 2023; (43(10)):1935-1945 doi:10.1007/s00296-023-05378-3.

    PMID: 37378685
  23. 23

    To what extent do the muscles and tendons influence metabolic cost and exercise tolerance in the hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders?

    Sheehan DS, Oliemans JP, Golden DW, et al.

    Clinical biomechanics (Bristol, Avon) 2026; (131()):106695 doi:10.1016/j.clinbiomech.2025.106695.

    PMID: 41253098

This page is for informational purposes and does not constitute medical advice about hEDS or HSD. Discuss diagnostic criteria, genetic testing, and symptoms such as dizziness or nerve pain with a qualified clinician.